tissue-specific immunomodulating bispecific antibodies (Pandion/Astellas)

N/A

Report date: 2025/01/26 17:20:37

Base Information

Drug Nametissue-specific immunomodulating bispecific antibodies (Pandion/Astellas)
Drug Alias Namepancreas-tethered immunomodulating bispecific antibodies (Pandion Therapeutics)pancreas-tethered immunomodulating bispecific antibodies (Pandion/Astellas)tissue-specific immunomodulating bispecific antibodies (Pandion Therapeutics)Type 1 diabetes program (Pandion Therapeutics)tissue-specific immunomodulating bispecific antibodies (Merck & Co Inc) +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionImmunomodulatorsLangerhans islet cell modulators
TargetsUpdating
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPandion Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPandion Therapeutics IncAstellas Pharma Inc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A